Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model

Levick, 2007, Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation, J Immunol, 178, 641, 10.4049/jimmunol.178.2.641 Sciulli, 2005, The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain, Pharmacol Rep, 57, 66 Claria, 2005, Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer, Curr Pharm Des, 11, 3431, 10.2174/138161205774370753 Wickelgren, 2004, Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation, Science, 303, 941, 10.1126/science.303.5660.941a Chen, 2006, Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention, Curr Cancer Drug Targets, 6, 613, 10.2174/156800906778742451 Evans, 2008, What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases, Trends Pharmacol Sci, 29, 72, 10.1016/j.tips.2007.11.006 Peters-Golden, 1998, Cell biology of the 5-lipoxygenase pathway, Am J Respir Crit Care Med, 157, S227, 10.1164/ajrccm.157.6.mar4 Ferguson, 2007, Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein, Science, 317, 510, 10.1126/science.1144346 Ago, 2007, Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis, Nature, 448, 609, 10.1038/nature05936 Charlier, 2003, Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs, Eur J Med Chem, 38, 645, 10.1016/S0223-5234(03)00115-6 Spector, 2004, Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function, Prog Lipid Res, 43, 55, 10.1016/S0163-7827(03)00049-3 Campbell, 2000, New role for epoxyeicosatrienoic acids as anti-inflammatory mediators, Trends Pharmacol Sci, 21, 125, 10.1016/S0165-6147(00)01472-3 Xu, 2006, Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors, Proc Natl Acad Sci USA, 103, 18733, 10.1073/pnas.0609158103 Node, 1999, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 285, 1276, 10.1126/science.285.5431.1276 Imig, 2005, Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases, Am J Physiol-Renal, 289, F496, 10.1152/ajprenal.00350.2004 Sarkis, 2004, Role of cytochrome P450 metabolites of arachidonic acid in hypertension, Curr Drug Metab, 5, 245, 10.2174/1389200043335603 Seubert, 2007, Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury, Prostaglandins Other Lipid Mediat, 82, 50, 10.1016/j.prostaglandins.2006.05.017 Elbekai, 2006, Cytochrome P450 enzymes: Central players in cardiovascular health and disease, Pharmacol Therapeut, 112, 564, 10.1016/j.pharmthera.2005.05.011 Doggrell, 2005, P-450: a new target in the heart and coronary circulation, Drug Future, 30, 261, 10.1358/dof.2005.030.03.884303 Newman, 2005, Epoxide hydrolases: their roles and interactions with lipid metabolism, Prog Lipid Res, 44, 1, 10.1016/j.plipres.2004.10.001 Morisseau, 2006, Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition, FASEB J, 20, A669, 10.1096/fasebj.20.4.A669 Imig, 2005, An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension, Hypertension, 46, 975, 10.1161/01.HYP.0000176237.74820.75 Zhao, 2002, Soluble epoxide hydrolase regulates renal microvascular angiotensin II reactivity in hypertension, FASEB J, 16, A418 Imig, 2002, Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension, Hypertension, 39, 690, 10.1161/hy0202.103788 Imig, 2006, Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors, Cardiovasc Drug Rev, 24, 169, 10.1111/j.1527-3466.2006.00169.x Schmelzer, 2005, Soluble epoxide hydrolase is a therapeutic target for acute inflammation, Proc Natl Acad Sci USA, 102, 9772, 10.1073/pnas.0503279102 Smith, 2005, Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor, Proc Natl Acad Sci USA, 102, 2186, 10.1073/pnas.0409591102 Olearczyk, 2009, Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats, Clin Sci (Lond), 116, 61, 10.1042/CS20080039 Inceoglu, 2007, Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs), Prostaglandins Other Lipid Mediat, 82, 42, 10.1016/j.prostaglandins.2006.05.004 Ng, 2006, Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1, Arterioscler Thromb Vasc, 26, 2462, 10.1161/01.ATV.0000242013.29441.81 Schmelzer, 2006, Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors, Proc Natl Acad Sci USA, 103, 13646, 10.1073/pnas.0605908103 Seubert, 2006, Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function, Circ Res, 99, 442, 10.1161/01.RES.0000237390.92932.37 Davis, 2006, Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition, J Pharmacol Exp Ther, 316, 815, 10.1124/jpet.105.091876 Jin, 2006, Cytochrome P450 epoxygenases provide a novel mechanism for penile erection, FASEB J, 20, 539, 10.1096/fj.05-4341fje Borgdorff, 2006, Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation, J Am Coll Cardiol, 48, 817, 10.1016/j.jacc.2006.03.053 Domoki, 2005, Selective inhibitors differentially affect cyclooxygenase-dependent pial arteriolar responses in newborn pigs, Pediatr Res, 57, 853, 10.1203/01.PDR.0000161415.62776.0A Leach, 1998, Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone, Br J Pharmacol, 124, 586, 10.1038/sj.bjp.0701869 Brindle, 2002, Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics, Nat Med, 8, 1439, 10.1038/nm1202-802 Lewis, 2008, Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury, J Clin Invest, 118, 3503, 10.1172/JCI35111 Lindon, 2005, The consortium for metabonomic toxicology (COMET): aims, activities and achievements, Pharmacogenomics, 6, 691, 10.2217/14622416.6.7.691 Fiehn, 2002, Metabolomics—the link between genotypes and phenotypes, Plant Mol Biol, 48, 155, 10.1023/A:1013713905833 Wikoff, 2008, Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques, J Clin Invest, 118, 2661, 10.1172/JCI34138 Yang, 2009, Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry, Anal Chem, 81, 8085, 10.1021/ac901282n Sinal, 2000, Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation, J Biol Chem, 275, 40504, 10.1074/jbc.M008106200 Luria, 2007, Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice, J Biol Chem, 282, 2891, 10.1074/jbc.M608057200 Hwang, 2007, Orally bioavailable potent soluble epoxide hydrolase (sEH) inhibitors, J Med Chem, 50, 3825, 10.1021/jm070270t Cyrus, 2002, Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice, Circulation, 106, 1282, 10.1161/01.CIR.0000027816.54430.96 Paul, 1999, Evidence supporting involvement of leukotrienes in LPS-induced hypothermia in mice, Am J Physiol-Reg I, 276, R52 Liu, 2009, Pharmacokinetic optimization of four soluble epoxide hydrolase (sEH) inhibitors for use in a murine model of inflammation, Br J Pharmacol, 156, 284, 10.1111/j.1476-5381.2008.00009.x Liu, 2009, Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo, Mol Cancer Ther, 8, 2193, 10.1158/1535-7163.MCT-09-0119 Capdevila, 1992, Cytochrome-P450 and the Arachidonate Cascade, FASEB J, 6, 731, 10.1096/fasebj.6.2.1537463 Weinberg, 1992, Lipopolysaccharide, tumor-necrosis-factor, and interleukin-1 interact to cause hypotension, J Lab Clin Med, 120, 205 Xing, 1998, IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses, J Clin Invest, 101, 311, 10.1172/JCI1368 Dettmer, 2004, Metabolomics—a new exciting field within the “omics” sciences, Environ Health Perspect, 112, A396, 10.1289/ehp.112-1241997 Back, 2007, 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation, Circ Res, 100, 946, 10.1161/01.RES.0000264498.60702.0d Jawien, 2006, Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice, Eur J Clin Invest, 36, 141, 10.1111/j.1365-2362.2006.01606.x Titos, 2005, Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells, J Leukoc Biol, 78, 871, 10.1189/jlb.1204747 Byrum, 1997, Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses, J Exp Med, 185, 1065, 10.1084/jem.185.6.1065 Voelkel, 1996, Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats, J Clin Invest, 97, 2491, 10.1172/JCI118696 Cianchi, 2006, Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells, Mol Cancer Ther, 5, 2716, 10.1158/1535-7163.MCT-06-0318 Picard, 1997, Ketorolac potentiates morphine in postoperative patient-controlled analgesia, Pain, 73, 401, 10.1016/S0304-3959(97)00128-0 Delaney, 2007, Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding, Can Med Assoc J, 177, 347, 10.1503/cmaj.070186 Graham, 1986, Aspirin and the stomach, Ann Intern Med, 104, 390, 10.7326/0003-4819-104-3-390